Display options
Cite
Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, et al. Effect of Atorvastatin versus Simvastatin on Lipid Profile and Plasma Fibrinogen in Patients with Hypercholesterolaemia: A Pilot, Randomised, Double-Blind, Dose-Titrating Study. Clin Drug Investig. 1998;16(3):219-27doi: 10.2165/00044011-199816030-00006.
Athyros, V. G., Papageorgiou, A. A., Hatzikonstandinou, H. A., Athyrou, V. V., & Kontopoulos, A. G. (1998). Effect of Atorvastatin versus Simvastatin on Lipid Profile and Plasma Fibrinogen in Patients with Hypercholesterolaemia: A Pilot, Randomised, Double-Blind, Dose-Titrating Study. Clinical drug investigation, 16(3), 219-27. https://doi.org/10.2165/00044011-199816030-00006
Athyros, V G, et al. "Effect of Atorvastatin versus Simvastatin on Lipid Profile and Plasma Fibrinogen in Patients with Hypercholesterolaemia: A Pilot, Randomised, Double-Blind, Dose-Titrating Study." Clinical drug investigation vol. 16,3 (1998): 219-27. doi: https://doi.org/10.2165/00044011-199816030-00006
Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, Athyrou VV, Kontopoulos AG. Effect of Atorvastatin versus Simvastatin on Lipid Profile and Plasma Fibrinogen in Patients with Hypercholesterolaemia: A Pilot, Randomised, Double-Blind, Dose-Titrating Study. Clin Drug Investig. 1998;16(3):219-27. doi: 10.2165/00044011-199816030-00006. PMID: 18370543.
Copy Download .nbib Format: NLM
Share it on

Clin Drug Investig. 1998;16(3):219-27. doi: 10.2165/00044011-199816030-00006.

Effect of Atorvastatin versus Simvastatin on Lipid Profile and Plasma Fibrinogen in Patients with Hypercholesterolaemia: A Pilot, Randomised, Double-Blind, Dose-Titrating Study.

Clinical drug investigation

V G Athyros, A A Papageorgiou, H A Hatzikonstandinou, V V Athyrou, A G Kontopoulos

Affiliations

  1. Lipid Out-Patient Clinic, Hippocration Hospital, Thessaloniki, Greece.

PMID: 18370543 DOI: 10.2165/00044011-199816030-00006

Abstract

OBJECTIVE: To investigate the effect of atorvastatin vs simvastatin on lipid profile and plasma fibrinogen in patients with hypercholesterolaemia.

PATIENTS: 30 outpatients (25 men), with a median age of 51 years were studied. Eight patients had established coronary artery disease (CAD) and four had diabetes mellitus at baseline. 11 patients presented a Frederickson's IIb phenotype and 19 a IIa phenotype at baseline.

STUDY DESIGN: After a 6-week placebo period, patients were randomly assigned to simvastatin (10 mg/day, n = 15) or atorvastatin (10 mg/day, n = 15). Lipid profile, apolipoproteins B and A-I and plasma fibrinogen were measured for a 16-week period, at 4-week intervals. Thereafter, the dose of each drug was doubled only in patients with low density lipoprotein cholesterol (LDL-C) levels above 130 mg/dl for a further 16-week period.

RESULTS: Ten of 15 patients on atorvastatin 10mg (66%) and four of 15 on simvastatin 10mg (27%) achieved the LDL-C <130 mg/dl goal. Apolipoprotein B was reduced by both drugs (-33%, p < 0.001 for atorvastatin and -18%, p < 0.05 for simvastatin), but plasma fibrinogen and triglyceride were reduced only by atorvastatin (-20%, p < 0.01; -36%, p < 0.001, respectively). During the second 16-week period seven of 11 patients receiving the simvastatin 20mg dose (64%) achieved the LDL-C <130 mg/dl goal. The comparison of atorvastatin 10mg with simvastatin 20mg showed that the drugs appear to be equipotent in terms of LDL-C lowering.

CONCLUSIONS: Atorvastatin in equipotent doses to simvastatin appeared to be more effective than the latter in reducing triglyceride and plasma fibrinogen in patients with hypercholesterolaemia, mainly in those with Frederickson's phenotype Iib.

References

  1. Arterioscler Thromb Vasc Biol. 1995 May;15(5):678-82 - PubMed
  2. JAMA. 1996 Jan 10;275(2):128-33 - PubMed
  3. Atherosclerosis. 1997 Apr;130(1-2):191-7 - PubMed
  4. N Engl J Med. 1996 Oct 3;335(14):1001-9 - PubMed
  5. Am J Cardiol. 1988 Nov 11;62(15):28J-34J - PubMed
  6. Lancet. 1994 Nov 19;344(8934):1383-9 - PubMed
  7. Am J Med. 1993 Apr;94(4):350-6 - PubMed
  8. JAMA. 1988 Oct 7;260(13):1917-21 - PubMed
  9. QJM. 1995 Jun;88(6):421-7 - PubMed
  10. Atherosclerosis. 1994 Oct;110 Suppl:S11-21 - PubMed
  11. Atherosclerosis. 1995 Oct;117(2):237-44 - PubMed
  12. Lancet. 1998 May 9;351(9113):1431; author reply 1431-2 - PubMed
  13. Am J Cardiol. 1997 Sep 1;80(5):608-13 - PubMed
  14. Am J Cardiol. 1997 Jul 1;80(1):39-44 - PubMed
  15. J Cardiovasc Risk. 1995 Jun;2(3):197-205 - PubMed
  16. Am J Cardiol. 1998 Mar 1;81(5):582-7 - PubMed
  17. Lancet. 1998 May 9;351(9113):1430; author reply 1431-2 - PubMed
  18. Br Heart J. 1995 Jul;74(1):14-7 - PubMed
  19. Coron Artery Dis. 1996 Nov;7(11):843-50 - PubMed
  20. Lancet. 1998 Feb 21;351(9102):569-70 - PubMed
  21. Arterioscler Thromb Vasc Biol. 1997 Aug;17(8):1527-31 - PubMed
  22. Circulation. 1993 Nov;88(5 Pt 1):2180-9 - PubMed
  23. Lancet. 1998 May 9;351(9113):1430-1; author reply 1431-2 - PubMed
  24. Am J Cardiol. 1995 Jul 13;76(2):8A-20A - PubMed
  25. Atherosclerosis. 1995 Jun;115(2):173-80 - PubMed
  26. N Engl J Med. 1995 Nov 16;333(20):1301-7 - PubMed
  27. Lancet. 1998 May 9;351(9113):1430; author reply 1431-2 - PubMed

Publication Types